Editorial Standards · Affiliate Disclosure · Next audit: July 29, 2026

Published: April 29, 2026

WEGOVY CARDIOVASCULAR PA — 2026 VERIFIED GUIDE

Wegovy Heart Disease Prior Authorization: The 2026 Approval Playbook

Here's the part almost every other page skips: the FDA approving Wegovy for heart disease in March 2024 didn't make insurance coverage automatic. Insurers wrote their own rules on top of the FDA label — and those rules are where most people get stuck. We pulled the public prior-authorization policies from UnitedHealthcare, Aetna/CVS Caremark, Wellmark, CareFirst, and Highmark, plus the CMS Medicare guidance, and what we found is that the same diagnosis can sail through one plan and get rejected by another for reasons nobody mentioned at your appointment.

This is the playbook to fix that.

Will the Wegovy heart-disease PA path probably work for you?

Find your situation in the table. The “best next step” column tells you where to focus energy — before you spend a dollar or a week on paperwork.

Tap to check your Wegovy coverage on Ro — free, no commitment required

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

What “heart disease” actually means to your insurance company (it's stricter than you think)

Insurers don't approve Wegovy for “heart disease” the way most people use that phrase. They approve it for established cardiovascular disease — and that distinction is where a meaningful share of the denials we reviewed originate. If your chart says “history of high cholesterol” but doesn't show a documented event, you're probably going to hit a wall on this pathway.

The FDA-approved cardiovascular indication for Wegovy, finalized in March 2024, applies to adults with established cardiovascular disease and either obesity or overweight — to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke). The clinical evidence is the SELECT trial: 17,604 adults with prior CVD and BMI ≥27 (no diabetes), followed for an average of about 40 months, with a 20% reduction in major adverse cardiovascular events versus placebo. That trial is the spine of every CV-indication PA approval today.

What insurers count as established CVD

What usually does not count by itself

Wegovy heart disease PA criteria crosswalk: what 6 major payers actually require

We assembled this table because the information doesn't exist anywhere else in one place. To get this on your own, you'd need to download UnitedHealthcare's commercial PA bulletin, Aetna's clinical policy bulletin 6410-C, CVS Caremark's 4774-C document, Wellmark's supplemental indications policy, CareFirst/Maryland Medicaid's Wegovy criteria, and Highmark's PA form — and read each one front to back.

What this table actually tells you

The doctor's CV-indication submission cheat sheet (print this and bring it)

Tap to check whether Ro's PA team can handle this for you

The 4 things every CV-indication PA should contain

1. Diagnosis coding accurate to the chart. Submit under the cardiovascular-risk-reduction indication with diagnosis coding that matches the patient's documented cardiovascular condition and overweight/obesity status. Ask your plan whether the cardiovascular code must be primary and which codes it expects on its form.
2. BMI documented at time of prescription, calculated from a measured height + weight in the chart.
3. Documentation of established CVD with event date(s) — the cardiology consult or hospital discharge summary is the strongest source.
4. Concurrent guideline-directed medical therapy (GDMT) — statin, antiplatelet, beta-blocker / ACE-ARB / ARNI as appropriate — or a documented reason for any agent that's not in the regimen.

ICD-10 codes commonly used (discuss with your prescriber and your plan)

Letter of Medical Necessity (LMN) skeleton

Bring this template to your appointment so the prescriber can adapt it to your actual records. Don't add diagnoses, medications, or history that aren't documented in your chart.

[Date]
[Insurer Medical Director / PA Department]
RE: Prior Authorization for Wegovy® (semaglutide)
Patient: [Name], DOB [date], Member ID [number]

Dear Reviewer,

I am requesting prior authorization for Wegovy under the cardiovascular
risk reduction indication (FDA-approved March 2024) for my patient, who
meets the FDA-labeled criteria as follows:

• Established cardiovascular disease:
  [diagnosis + ICD-10 code + event date — e.g., "Prior MI, I25.2,
  documented [date], see attached cardiology note"]
• BMI: [measured value] (recorded [date])
• Concurrent cardiac therapy: [statin name/dose, antiplatelet
  name/dose, beta-blocker/ACE-ARB/ARNI as appropriate, OR a documented
  contraindication or intolerance]
• Lifestyle modification: [diet + activity counseling, dates]

The SELECT trial (Lincoff et al., NEJM 2023) demonstrated a 20%
relative risk reduction in major adverse cardiovascular events in
adults with this clinical profile.

Attachments:
☐ Cardiology consult note(s) / hospital discharge summary
☐ Most recent BMI documentation (height + weight + date)
☐ Current medication list
☐ Recent labs (lipid panel, A1C, eGFR)
☐ Lifestyle modification documentation
☐ [Insurer-specific PA form, completed]

[Provider name], [credentials], NPI [number]
[Signature, date]

Documentation checklist

Why Wegovy heart disease PAs get denied — and the exact fix for each one

Most denials on the cardiovascular pathway trace back to one of six specific causes — usually a missing record or wrong-indication framing rather than true ineligibility. A denial letter looks scary but it's not the end. It's a checklist of what your plan didn't see. Read the exact reason in the letter — not just the headline — and treat it as a punch list.

The peer-to-peer review — the underused move

If a denial looks wrong on its face, your prescriber can request a peer-to-peer (P2P) review — a brief phone call, usually 10–15 minutes, with the insurance medical director. P2P calls reverse a meaningful share of borderline denials, often without a formal appeal. Your prescriber's office has to actively request it; many won't unless you ask.

External review — the option after internal appeals fail

Once internal appeals are exhausted, you can request an external review by an independent third party. For ACA-regulated commercial plans, this is a federal right; for Medicare, this is the IRE (Independent Review Entity) step. KFF found that 80.7% of appealed Medicare Advantage prior-authorization denials were fully or partly overturned in 2024 — but only 11.5% of denials were appealed in the first place. A first denial isn't a final answer, but most patients leave the appeal on the table.

One honest trade-off we want you to know about before you go further

Even when your PA is approved, your monthly cost depends entirely on your plan's tier structure, deductible, and savings-card eligibility. Wegovy on a commercial plan can cost very little or several hundred dollars out of pocket, depending on those variables. The Wegovy savings card may reduce eligible commercially insured patients' cost to as little as $25 per prescription — but it doesn't apply to Medicare, Medicaid, TRICARE, or other government programs. And if your “heart disease” is actually borderline-high blood pressure or one borderline lipid panel, the CV-indication path won't open even with perfect paperwork. The criteria require established disease, not risk factors.

Ro doesn't offer the cheapest cash-pay GLP-1 on the market. If your only priority is the lowest absolute monthly bill and you're willing to skip insurance entirely, NovoCare lists the Wegovy injection at $199/month for early starter doses (through June 30, 2026), $349/month for the 0.25 mg through 2.4 mg doses, and $399/month for Wegovy HD 7.2 mg, with Wegovy tablets at $149/month for the 1.5 mg and 4 mg starter doses. But Ro can offer the thing this audience actually needs more: an insurance concierge that helps with the PA submission, follows up with your insurer, and helps with appeals when coverage is denied.

If your priority is the lowest absolute monthly cost and you're willing to skip insurance entirely — read Best Telehealth for Wegovy for self-pay paths →

Medicare Part D vs. the Medicare GLP-1 Bridge — which path pays for Wegovy for heart disease?

Wegovy CV indication on Medicare (Part D path)

When Wegovy is prescribed for cardiovascular risk reduction in an adult with established CVD and BMI ≥27, Medicare Part D plans may cover it — because this is a non-weight-loss indication, it's not blocked by the federal weight-loss drug exclusion at 42 U.S.C. § 1395w-102. Whether your specific Part D plan covers it is a formulary question — coverage and PA criteria vary plan by plan.

Submission goes through your Part D plan's standard PA process. Your prescriber attests that you meet:

• Established cardiovascular disease (with appropriate diagnosis coding)
• BMI ≥27
• Standard cardiac care or documented exception
• Lifestyle modification per FDA label

For Medicare Part D coverage determinations, the plan generally must respond within 24 hours for expedited requests or 72 hours for standard requests. If you're appealing a denial through redetermination, the timeframe is 72 hours expedited or 7 calendar days standard.

Medicare GLP-1 Bridge (the weight-loss path — different program)

The Bridge is a CMS demonstration running July 1, 2026 through December 31, 2027, providing eligible Medicare Part D beneficiaries with a $50 cost-sharing amount for select GLP-1 drugs prescribed to reduce excess body weight. CMS lists the Bridge-covered drugs as Foundayo, Wegovy injection, Wegovy tablets, and Zepbound KwikPen. The Bridge uses a CMS central processor — not your Part D plan — for prior authorization and claims.

The 5 levels of Medicare Part D appeal (most patients give up at level 1)

1. Redetermination — your plan re-reviews the denial (72 hours expedited / 7 calendar days standard)
2. Reconsideration — Independent Review Entity (IRE) review
3. Administrative Law Judge (ALJ) hearing — for disputes meeting the dollar threshold
4. Medicare Appeals Council review
5. Federal District Court

KFF found 80.7% of appealed Medicare Advantage PA denials were overturned in 2024. The lesson: a first denial isn't a final answer.

Should your cardiologist, PCP, or telehealth provider submit the PA?

The best prescriber for your Wegovy CV-indication PA is whoever can document the criteria most completely. A cardiologist usually has the strongest CVD records; a PCP can work if they can pull cardiology notes into the submission; Ro shines when you want the insurance paperwork handled for you on a commercial plan. CareFirst/Maryland Medicaid actually requires cardiologist involvement — check your plan first.

Edge cases: type 2 diabetes, heart failure, and “risk factors only” patients

If you have type 2 diabetes + established CVD

Several major plans (Aetna, CVS Caremark, Wellmark, UnitedHealthcare commercial) explicitly exclude patients with type 2 diabetes from the Wegovy cardiovascular-risk PA pathway. UHC's policy excludes patients with diabetes or HbA1c >6.5%. The reasoning isn't punitive — these plans typically prefer that T2D patients with cardiovascular disease use a diabetes-indicated therapy.

What to do: Ask your prescriber whether Ozempic (semaglutide for T2D) fits your plan's criteria — Ozempic carries an FDA-labeled MACE-reduction indication for adults with type 2 diabetes and established CVD, and that's exactly what payer policies reference for re-routing.

If you have NYHA Class IV heart failure

UnitedHealthcare's commercial CV-indication policy specifically excludes NYHA class IV heart failure patients from the Wegovy cardiovascular pathway. Other plans may or may not have similar exclusions — verify with your specific plan. Talk to your cardiologist about whether the exclusion applies to your clinical profile.

If you have a recent history of pancreatitis

Wellmark's policy includes exclusion language for pancreatitis within the last 180 days. Document the date of the pancreatitis episode, current resolution status, and any specialist clearance. Some plans will accept GLP-1 therapy after a documented recovery period; ask your gastroenterologist or cardiologist before pursuing the PA.

If you have only risk factors (high cholesterol, hypertension, family history)

This is the most common “false positive” we see. People hear that insurance covers Wegovy for heart disease and assume risk factors qualify. They almost never do on this pathway. The CV indication requires documented established disease — a prior event or confirmed diagnosis — not modifiable risk factors.

• If you have insurance that covers weight-loss medications: pursue the weight-loss PA pathway separately. Many commercial plans cover Wegovy for chronic weight management at BMI ≥27 with one weight-related comorbidity (which can include hypertension or hyperlipidemia).
• If you have Medicare and want Wegovy for weight loss: the Medicare GLP-1 Bridge (July 2026 – December 2027) may apply. See Medicare GLP-1 Bridge Program Explained →
• If you're paying out of pocket: see Best Telehealth for Wegovy →

If you have prediabetes

Prediabetes typically doesn't trigger the diabetes carve-out (which is usually triggered by A1C ≥6.5% or a documented T2D diagnosis). But verify — some plans use HbA1c >6.0% as the cutoff. If you're borderline, the prescriber's note should reflect your most recent HbA1c clearly.

If you have prior revascularization but no documented MI/stroke

Some plans (Aetna, CVS Caremark) explicitly count prior CABG, PCI, or angioplasty as qualifying CVD. Others focus on prior MI/stroke/PAD as the trio. Check your plan's specific language before submitting. If your CABG or stent is your only CVD evidence, make sure your plan accepts it.

How long Wegovy PA takes — and how long your approval lasts

Plan for 1–2 weeks from your prescriber submitting a clean Wegovy PA to your prescription being filled on a commercial plan. Medicare adds a few days. If you're denied and have to appeal, add 30–60 days. Initial approval lengths range from 6 months (Wellmark) to 12 months (UHC, CVS Caremark). Mark your calendar — missed renewals cause coverage gaps as painful as missed initial PAs.

Approval lengths by insurer

Renewal checklist (so you don't lose coverage at month 6 or month 7)

Real voices: what people are actually confused about

Direct quotes from real patients navigating this problem — included as voice-of-customer evidence, not medical or insurance authority.

The first poster's question is exactly what this page is for: yes, it's possible — when the PA is submitted under the cardiovascular indication and the chart shows established CVD. The second poster ran into the most common trap: high cholesterol alone is a risk factor, not established CVD, and most plans won't approve the CV pathway on risk factors alone. The third poster's denial was processed under the weight-loss benefit — a different submission framing might unlock the same plan.

“Wegovy has been the most positive life-changing medication I have ever used.”— Drugs.com user review

⚠️ Results aren't typical, and user reviews don't constitute clinical evidence. Wegovy is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity. For clinical evidence on the cardiovascular indication, see the SELECT trial (Lincoff et al., NEJM 2023) and the Wegovy prescribing information.

Your 7-step action plan, starting today

1. 1Call your insurer or use the member portal to request the Wegovy prior authorization criteria. Ask specifically for the cardiovascular indication criteria (not the weight-loss criteria). Save the document.
2. 2Confirm whether your plan has the diabetes carve-out if you have type 2 diabetes. If yes, ask whether Ozempic (under the diabetes indication) is the better path.
3. 3Pull your CVD records. Your cardiology consult note or hospital discharge summary is your single strongest piece of evidence. Get a copy before your prescriber appointment.
4. 4Get your most recent BMI documented (within 90 days if you're on a strict plan like CareFirst or Wellmark). A quick in-office weight and height check suffices.
5. 5Confirm your current cardiac meds list — statin, antiplatelet, beta-blocker / ACE-ARB / ARNI as appropriate. If anything is missing, your prescriber needs a documented reason.
6. 6Ask the prescriber to submit under the cardiovascular indication with diagnosis coding that accurately matches your records. Bring the cheat sheet from this guide.
7. 7If denied, read the denial letter carefully and resubmit or appeal addressing the specific reason cited. The peer-to-peer review and external review options are real — use them.

Frequently asked questions about Wegovy heart disease prior authorization

Still not sure which GLP-1 path fits your situation?

The criteria here cover the majority of cases, but every reader's specific combination of insurance, conditions, and history is different. If your plan has a wrinkle we didn't cover — or you're not sure whether the CV pathway, the weight-loss pathway, or self-pay makes sense for you — take our free 60-second matching quiz.

If you're ready, here's the lowest-friction first step

You've read the criteria. You know what your plan is likely to ask for. You know the difference between the CV indication and the weight-loss pathway. The remaining question: do you want to coordinate the coverage check and PA submission yourself, or get help from a service that handles this every day?

Ro's free GLP-1 Insurance Coverage Checker is the lowest-commitment first step for commercially insured readers. It contacts your insurer, sends you a personalized coverage report by email, and tells you exactly what your plan requires before you decide on anything else. No membership signup required to use the checker.